Evaluation of Various Doses of Ro 27-2771 (Test Drug) in Asthmatic Patients Not Treated With Inhaled Corticosteroids
NCT ID: NCT00048009
Last Updated: 2017-06-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
INTERVENTIONAL
2002-10-25
2004-02-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Inhaled Corticosteroid Replacement Study - Efficacy and Safety of Ro 27-2441 (Test Drug) in Moderate Persistent Asthma
NCT00048022
A Single Ascending Dose Study of R1671 in Patients With Mild Intermittent Asymptomatic Asthma.
NCT00517816
A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma
NCT02918019
Single Dose Study to Assess Efficacy, Safety and Tolerability of LAS100977 in Asthmatic Patients.
NCT01425801
A Study of RO5036505 in Patients With Moderate to Severe Asthma
NCT00967590
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dual Integrin Antagonist
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Current treatment for asthma with short acting inhaled beta 2 agonists (such as albuterol) only
* In good health ad demonstrated by medical history and physical exam
* Negative urine pregnancy test
* Commitment to use two forms of effective contraception simultaneously throughout the study duration and for one month after discontinuing therapy
Exclusion Criteria
* History of severe asthma necessitating the use of oral/injectable corticosteroids within the last 2 months and/and or two bursts in the last year
* Undergoing allergy shots unless on a stable maintenance dose for three months before the start of the study
* History of chronic pulmonary diseases other than asthma
* Treatment of conditions other than asthma with oral corticosteroids within one month of the start of the study
* Current tobacco use
* Smoking history of greater than 10 pack-year history of cigarette smoking (number of packs smoked per day times the number of years smoked)
* History or evidence of drug or alcohol abuse
* Diagnosis or evidence of an infectious illness within one month of Visit 1
* Clinically significant diseases as assessed by the study doctor
* Participation in another clinical study with an experimental drug within one month of start of the study
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Scottsdale, Arizona, United States
Huntington Beach, California, United States
Long Beach, California, United States
Los Angeles, California, United States
Los Angeles, California, United States
Palmdale, California, United States
San Diego, California, United States
San Diego, California, United States
San Diego, California, United States
San Jose, California, United States
Walnut Creek, California, United States
Denver, Colorado, United States
Denver, Colorado, United States
Louisville, Colorado, United States
Wheat Ridge, Colorado, United States
Hartford, Connecticut, United States
Tallahassee, Florida, United States
Tamarac, Florida, United States
Tampa, Florida, United States
Tampa, Florida, United States
Atlanta, Georgia, United States
Savannah, Georgia, United States
Chicago, Illinois, United States
Normal, Illinois, United States
River Forest, Illinois, United States
Indianapolis, Indiana, United States
Iowa City, Iowa, United States
Lenexa, Kansas, United States
Metairie, Louisiana, United States
North Dartmouth, Massachusetts, United States
Minneapolis, Minnesota, United States
St Louis, Missouri, United States
Missoula, Montana, United States
Omaha, Nebraska, United States
Las Vegas, Nevada, United States
Cherry Hill, New Jersey, United States
Princeton, New Jersey, United States
Teaneck, New Jersey, United States
Farmingdale, New York, United States
Rochester, New York, United States
Rockville Centre, New York, United States
Elizabeth City, North Carolina, United States
Canton, Ohio, United States
Cincinnati, Ohio, United States
Medford, Oregon, United States
Portland, Oregon, United States
Easton, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Upland, Pennsylvania, United States
Providence, Rhode Island, United States
Charleston, South Carolina, United States
Charleston, South Carolina, United States
Austin, Texas, United States
Dallas, Texas, United States
Dallas, Texas, United States
El Paso, Texas, United States
San Antonio, Texas, United States
Sugar Land, Texas, United States
Murray, Utah, United States
Kirkland, Washington, United States
Seattle, Washington, United States
Spokane, Washington, United States
Tacoma, Washington, United States
Wenatchee, Washington, United States
Morgantown, West Virginia, United States
Madison, Wisconsin, United States
Milwaukee, Wisconsin, United States
Adelaide, , Australia
Brisbane, , Australia
Melbourne, , Australia
Perth, , Australia
Sydney, , Australia
Woodville, , Australia
Vancouver, British Columbia, Canada
Hamilton, Ontario, Canada
Toronto, Ontario, Canada
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Québec, Quebec, Canada
Chihuahua City, , Mexico
Guadalajara, , Mexico
Mexico City, , Mexico
Mexico City, , Mexico
Mexico City, , Mexico
Mérida, , Mexico
México, , Mexico
Monterrey, , Mexico
Monterrey, , Mexico
Puebla City, , Mexico
Ponce, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BA16631
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.